Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Veracyte Expands Early Access for Genomic Lung Disease Classifier

Veracyte Expands Early Access for Genomic Lung Disease Classifier

Dec 06, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Veracyte said yesterday that it has expanded the early-access program (EAP) for its Envisia Genomic Classifier for differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs).

Veracyte launched the EAP in May to provide advance access to the test in anticipation of a nationwide launch in 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

And Maybe Not

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Now Onto a Hungry Caterpillar

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

This Variant Here

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

Nature Papers Present Tool for Topological Analysis of Chromosomes, Map of Genome-Lipid Associations

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.

What's Popular?

In Business News

  1. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  2. Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

  3. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  4. Metabolon Closes $72M in Debt and Equity Funding

  5. Ionpath Closes $18M Series B Round

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.